Enrollment Complete in Microcyn Trial

Oculus Innovative Sciences has finished enrollment of its Phase II trial of Microcyn for the treatment of mildly infected diabetic foot ulcers.

The 67-patient, open-label study, which is being conducted at 15 U.S. sites, is designed to demonstrate that topical Microcyn has similar cure and improvement rates as oral levofloxacin.

Oculus said it expects to provide preliminary top line results in the first calendar quarter of 2008.